Atorvastatin-linked rhabdomyolysis caused by the simultaneous intake of amoxicillin clavulanic acid

Mariarosaria De Luca; Olimpia Iacono; Rosa Lucci; Vincenzo Guardasole; Giorgio Bosso; Antonio Cittadini; Ugo Oliviero

doi:10.1515/jbcpp-2020-0108

Article

Atorvastatin-linked rhabdomyolysis caused by the simultaneous intake of amoxicillin clavulanic acid

Mariarosaria De Luca , Olimpia Iacono , Rosa Lucci , Vincenzo Guardasole , Giorgio Bosso , Antonio Cittadini and Ugo Oliviero

Published/Copyright: September 9, 2020

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Basic and Clinical Physiology and Pharmacology Volume 32 Issue 1

Abstract

Objectives

Rhabdomyolysis is a rare syndrome in which a serious muscle damage suddenly appears, with the possible occurrence of severe complications such as kidney failure, electrolyte imbalances and death, and represents the most severe form of statin-induced muscle injury.

Case presentation

Here we present the case of a 55-year-old woman who started therapy with amoxicillin clavulanic acid on a background of atorvastatin therapy, resulting in rhabdomyolysis.

Conclusions

This case highlights the importance of evaluating potential drug interactions in patients taking statin and the need of monitoring clinical and laboratory findings suggestive of rhabdomyolysis.

Keywords: atorvastatin; rhabdomyolysis; statin

Corresponding author: Ugo Oliviero, Department of Translational Medical Sciences, University Federico II, Via Sergio Pansini 5, Naples, Italy, E-mail: ugo.oliviero@unina.it

Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The local Institutional Review Board deemed the study exempt from review.

References

1. Postmus, I, Verschuren, J, de Craen, A, Slagboom, P, Westendorp, R, Jukema, J, et al. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics 2012;13:831–40. https://doi.org/10.2217/pgs.12.25.Search in Google Scholar PubMed

2. Mach, F, Baigent, C, Catapano, AL, Koskinas, KS, Casula, M, Badimon, L, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European. Atheroscler Soc Eur Heart J 2019;2020:111–88. https://doi.org/10.1093/eurheartj/ehz455.Search in Google Scholar PubMed

3. Tobert, JA, Newman, CB. Statin tolerability: in defence of placebo-controlled trials. Eur J Prev Cardiol 2016;23:891–6. https://doi.org/10.1177/2047487315602861.Search in Google Scholar PubMed PubMed Central

4. Banach, M, Rizzo, M, Toth, PP, Farnier, M, Davidson, MH, Al-Rasadi, K, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015;11:1–23. https://doi.org/10.5114/aoms.2015.49807.Search in Google Scholar PubMed PubMed Central

5. Steffel, J, Verhamme, P, Potpara, TS, Albaladejo, P, Antz, M, Desteghe, L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330–93. https://doi.org/10.1093/eurheartj/ehy136.Search in Google Scholar PubMed

6. Etemad, L. Statins and potentially interacting medications: a managed care perspective. AJMC; 2004.Search in Google Scholar

7. Thompson, PD, Clarkson, P, Karas, RH. Statin-associated myopathy. J Am Med Assoc 2003;289:1681–90. https://doi.org/10.1001/jama.289.13.1681.Search in Google Scholar PubMed

8. deLemos, AS, Ghabril, M, Rockey, DC, Gu, J, Barnhart, HX, Fontana, RJ, et al. Drug-induced liver injury network (DILIN). Amoxicillin-clavulanate-induced liver injury. Dig Dis Sci 2016;61:2406–16. https://doi.org/10.1007/s10620-016-4121-6.Search in Google Scholar PubMed PubMed Central

9. Naranjo, CA, Busto, U, Sellers, EM, Sandor, P, Ruiz, I, Roberts, EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45. https://doi.org/10.1038/clpt.1981.154.Search in Google Scholar PubMed

10. Weibrecht, K, Dayno, M, Darling, C, Bird, SB. Liver aminotransferases are elevated with rhabdomyolysis in the absence of significant liver injury. J Med Toxicol 2010;6:294–300. https://doi.org/10.1007/s13181-010-0075-9.Search in Google Scholar PubMed PubMed Central

11. Lim, AKH. Abnormal liver function tests associated with severe rhabdomyolysis. World J Gastroenterol 2020;26:1020–8. https://doi.org/10.3748/wjg.v26.i10.1020.Search in Google Scholar PubMed PubMed Central

12. Jo, KM, Heo, NY, Park, SH, Moon, YS, Kim, TO, Park, J, et al. Serum aminotransferase level in rhabdomyolysis according to concurrent liver disease. Korean J Gastroenterol 2019;74:205–11. https://doi.org/10.4166/kjg.2019.74.4.205.Search in Google Scholar

13. Goessling, W, Friedman, LS. Increased liver chemistry in an asymptomatic patient. Clin Gastroenterol Hepatol 2005;3:852–8. https://doi.org/10.1016/s1542-3565(05)00416-7.Search in Google Scholar

14. Giannini, EG, Testa, R, Savarino, V. Liver enzyme alteration: a guide for clinicians. Can Med Assoc J 2005;72:367–79. https://doi.org/10.1503/cmaj.1040752.Search in Google Scholar PubMed PubMed Central

Received: 2020-04-21

Accepted: 2020-06-12

Published Online: 2020-09-09

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jbcpp-2020-0108

Keywords for this article

atorvastatin; rhabdomyolysis; statin